Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.

BACKGROUND: Risk models to predict prostate cancer on biopsy, whether they include only prostate-specific antigen (PSA) or other markers, are intended for use in all men of screening age. However, the association between PSA and cancer probably depends on a man's recent screening history. METHO...

Descripció completa

Dades bibliogràfiques
Autors principals:	Vickers, A, Cronin, A, Aus, G, Pihl, C, Becker, C, Pettersson, K, Scardino, P, Hugosson, J, Lilja, H
Format:	Journal article
Idioma:	English
Publicat:	2010

Ítems similars

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
per: Vickers, A, et al.
Publicat: (2008)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
per: Scardino Peter T, et al.
Publicat: (2008-07-01)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
per: Zackrisson, B, et al.
Publicat: (2003)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
per: Hugosson, J, et al.
Publicat: (2003)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
per: Vickers, A, et al.
Publicat: (2010)

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
per: Hugosson, J, et al.
Publicat: (2003)

Screening for prostate cancer.
per: Carlsson, S, et al.
Publicat: (2012)

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.
per: Hugosson, J, et al.
Publicat: (2000)

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
per: Hugosson, J, et al.
Publicat: (2004)

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
per: Bruun, L, et al.
Publicat: (2005)

Screening for prostate cancer: To the editor
per: Carlsson, S, et al.
Publicat: (2012)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
per: Becker, C, et al.
Publicat: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
per: Becker, C, et al.
Publicat: (2003)

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
per: Aus, G, et al.
Publicat: (2003)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
per: Vickers, A, et al.
Publicat: (2009)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
per: Aus, G, et al.
Publicat: (2004)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
per: Vickers, A, et al.
Publicat: (2010)

Screening for prostate cancer: an update.
per: Shariat, S, et al.
Publicat: (2008)

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
per: Vickers, A, et al.
Publicat: (2010)

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
per: Aus, G, et al.
Publicat: (2005)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
per: Gupta, A, et al.
Publicat: (2010)

Erratum: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section (International Journal of Cancer (2007) 120, (170-174))
per: Khatami, A, et al.
Publicat: (2007)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
per: Bangma, C, et al.
Publicat: (2010)

Mortality results from the Goteborg randomised population-based prostate-cancer screening trial.
per: Hugosson, J, et al.
Publicat: (2010)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
per: Vickers, A, et al.
Publicat: (2010)

Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.
per: Aus, G, et al.
Publicat: (2007)

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
per: Zackrisson, B, et al.
Publicat: (2004)

Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees.
per: Bergdahl, A, et al.
Publicat: (2009)

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
per: Carlsson, S, et al.
Publicat: (2012)

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.
per: Khatami, A, et al.
Publicat: (2007)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
per: Savage, C, et al.
Publicat: (2010)

Prostate cancer: estimating the benefits of PSA screening.
per: Vickers, A, et al.
Publicat: (2009)

Screening for prostate cancer: early detection or overdetection?
per: Vickers, A, et al.
Publicat: (2012)

Urological cancer: Time for another rethink on prostate cancer screening.
per: Vickers, A, et al.
Publicat: (2012)

Lead time associated with screening for prostate cancer.
per: Törnblom, M, et al.
Publicat: (2004)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
per: Lilja, H, et al.
Publicat: (2008)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
per: Avery, K, et al.
Publicat: (2012)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy
per: Avery, K, et al.
Publicat: (2012)

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
per: Roobol, M, et al.
Publicat: (2009)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
per: Vickers, A, et al.
Publicat: (2010)